Skip to main content
. 2017 Jul 28;8(47):82609–82620. doi: 10.18632/oncotarget.19664

Figure 5. Silencing TIMP-1 fails to abrogate the prometastatic phenotype of BE(2)-C/LM2.

Figure 5

(A) TIMP-1 silencing by shRNA was confirmed by immunoblotting. (B) No difference in in vivo bioluminescence was observed between BE(2)-C/LM2/shCON and BE(2)-C/LM2/shTIMP-1. (C) Liver explant weights (p= 0.95) and (D) bioluminescence were similar between the two groups (p= 0.55).